Leading investments from BPC's Future Fund: Breakthrough direct investment programme into stand out UK life sciences companies across biotech, techbio and health tech at Series A - crossoverResponsible for fund reporting, deal origination, execution, and portfolio management plus refining and communicating BPC’s investment strategy in the life sciences sector

Led 5 new investments into the portfolio of 42Portfolio Management responsibility for 12 Seed to Series A businesses (Board Observer)Led release of investment tranches and follow-on investment decisions into the portfolioCompanies included: - Monument Therapeutics: A company developing digital biomarkers in combination with repurposed drugs to improve patient stratification and treatment options for CNS disorders like neuroinflammation and cognitive impairment (a negative symptom of Schizophrenia) - Rinicare: a digital health company that has developed a predictive algorithm capable of notifying clinicians about risk of patient deterioration on the ICU ahead of time (STABILITY - currently undergoing RCT in Manchester Foundation Trust)- PBL Biotechnology: a company providing ex-vivo organ models to industry for use in pre-clinical evaluation of novel therapeutics and medical devices- Maxwellia: an OTC switch company that made the pill available for women outside of the doctors office, launching in >3000 Boots stores nationwide as the first of a product pipeline that is seeking to reduce the burden on primary carePlus companies using computational neural net models to detect early signs of tooth decay on dental X-rays, and the construction of knowledge graphs to generate novel insights from existing scientific and medical literature